Florida Medical Marijuana Licensing: Complete Guide to MMTC Applications

Executive Summary

Florida's Department of Health proposed a permanent medical marijuana licensing framework in September 2026 that would charge applicants $146,000 and limit application windows to five-day periods, marking a significant shift from the state's decade-old vertically integrated license model. The proposed rule, published for public comment, would establish the first new pathway for Medical Marijuana Treatment Center (MMTC) licenses since 2017, when Florida capped the number of operators at a formula tied to registered patient counts. The $146,000 fee represents one of the highest application costs in any U.S. medical cannabis program, while the compressed five-day application windows would create intense competition among prospective operators. The framework arrives as Florida's medical marijuana program serves more than 800,000 registered patients through 25 existing licensees, generating over $2 billion in annual sales. Industry stakeholders have raised concerns about the high barriers to entry and the potential for the brief application windows to favor well-capitalized multi-state operators over local entrepreneurs. The proposed rules would maintain Florida's vertical integration requirement, mandating that licensees control cultivation, processing, and retail operations under a single entity.

Why This Matters

The proposed licensing framework will determine who controls access to medical cannabis for Florida's 800,000-plus registered patients and shape the competitive landscape of a $2+ billion annual market. Florida operates the third-largest medical marijuana program in the United States by patient count, behind only California and Oklahoma. The state's existing 25 licensees include major multi-state operators such as Trulieve, Curaleaf, and Verano, alongside Florida-based companies like Surterra Wellness and Liberty Health Sciences. The $146,000 application fee alone exceeds the total startup costs for cultivation licenses in states such as Oklahoma and Michigan, where application fees range from $2,500 to $6,000. Combined with the capital requirements for vertical integration—estimated at $5 million to $15 million for cultivation facilities, processing labs, and retail dispensaries—the framework effectively limits participation to well-funded corporations and excludes smaller operators, social equity applicants, and craft cultivators. For patients, the licensing structure directly impacts product diversity, pricing, and geographic access. Florida's existing vertical integration model has produced limited strain variety compared to states with independent cultivation and retail tiers. Wholesale markets in states like Colorado and Oregon feature hundreds of distinct cultivators, while Florida patients choose from products grown by just 25 companies. The proposed framework would perpetuate this consolidation unless the state issues licenses at scale. For investors and operators, the five-day application windows create a high-stakes competitive environment. Multi-state operators with dedicated regulatory teams and legal counsel hold structural advantages over local applicants in navigating compressed timelines. The framework also raises questions about the state's commitment to expanding access versus protecting incumbent licensees, who collectively operate more than 600 dispensaries statewide and have invested hundreds of millions in infrastructure under the assumption of limited competition.

Background and History

The Compassionate Medical Cannabis Act of 2014

Florida's medical marijuana program originated with the Compassionate Medical Cannabis Act of 2014, which authorized low-THC cannabis for patients with severe epilepsy and other debilitating conditions. The law, codified in Florida Statutes § 381.986, limited THC content to 0.8 percent and required CBD content of at least 10 percent. The Florida Department of Health awarded five regional licenses in 2015 to nurseries that had operated continuously for at least 30 years in the state, a requirement designed to ensure agricultural expertise but that also restricted entry to established horticultural businesses. The 2014 framework did not permit smokable flower or high-THC products, and qualifying conditions were narrowly defined. By early 2016, fewer than 1,000 patients had registered for the program, and only two of the five licensed operators had begun dispensing products. The limited patient uptake and restrictive product forms set the stage for broader reform.

Amendment 2 and the 2016 Voter Initiative

Florida voters approved Amendment 2 in November 2016 with 71 percent support, expanding the medical marijuana program to include a broad range of debilitating conditions and full-strength THC products. The constitutional amendment, which took effect in January 2017, required the Florida Legislature to implement regulations by July 2017. Amendment 2 defined qualifying conditions to include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, multiple sclerosis, and other conditions of the same kind or class as determined by a licensed physician. The amendment mandated that the Department of Health issue additional MMTC licenses if the number of registered patients exceeded 250,000, with one new license required for every 100,000 additional patients. This formula-based expansion mechanism replaced the fixed five-license cap from 2014 and established the framework that governs license issuance through 2026.

Senate Bill 8-A and Implementation Regulations (2017)

The Florida Legislature passed Senate Bill 8-A in June 2017, implementing Amendment 2 and establishing the regulatory structure for the expanded medical marijuana program. The law maintained the vertical integration requirement from 2014, mandating that MMTCs cultivate, process, transport, and dispense all products under a single license. Vertical integration was justified by state officials as necessary for seed-to-sale tracking and quality control, though critics argued it created monopolistic market conditions and high barriers to entry. Senate Bill 8-A initially prohibited smokable flower, limiting patients to oils, tinctures, capsules, and vaporizable concentrates. This restriction sparked immediate legal challenges. In 2018, Leon County Circuit Court Judge Karen Gievers ruled that the smokable ban violated the intent of Amendment 2, and the state declined to appeal. The Legislature repealed the ban in March 2019 through Senate Bill 182, and smokable flower became available to patients in April 2019. The 2017 law also established application requirements for new licenses, including a $60,063 non-refundable application fee, proof of $5 million in liquid assets, and demonstrated technical and cultivation expertise. The Department of Health conducted application rounds in 2017 and 2018, awarding 10 additional licenses beyond the original five low-THC operators. However, the application process was marred by litigation, with unsuccessful applicants challenging scoring methodologies and alleged procedural irregularities. Several lawsuits remained pending in 2026.

License Cap Litigation and the Florigrown Case

Florigrown, a Florida-based applicant denied a license in 2017, filed a lawsuit alleging that the Department of Health's licensing process violated competitive procurement requirements and favored politically connected operators. In May 2022, a Leon County jury awarded Florigrown $6.19 million in damages, finding that the state had acted in bad faith by structuring the application process to benefit incumbent licensees. The verdict represented a rare legal defeat for the state's cannabis regulatory framework and intensified scrutiny of the licensing process. The Florida Department of Health appealed the verdict, and the case remained in appellate proceedings as of September 2026. The Florigrown litigation underscored persistent concerns about transparency, fairness, and political influence in Florida's cannabis licensing, concerns that resurfaced with the announcement of the 2026 proposed framework.

Patient Growth and Market Expansion (2018-2026)

Florida's medical marijuana patient registry grew from 150,000 in early 2018 to more than 800,000 by mid-2026, making it one of the fastest-growing programs in the United States. The Department of Health issued additional licenses in phases as patient counts triggered the formula in Amendment 2, reaching 25 active MMTCs by 2023. Registered patients qualified through physician certifications for conditions including chronic pain, anxiety, PTSD, cancer, and terminal illnesses. Annual sales grew from approximately $300 million in 2018 to over $2 billion by 2025, according to industry analysts. Trulieve emerged as the dominant operator, controlling roughly 50 percent of market share through aggressive retail expansion and vertical integration. The company operated more than 200 dispensaries in Florida by 2026, with cultivation facilities exceeding 1 million square feet of canopy. Other major operators included Curaleaf, Surterra Wellness, Verano, and Ayr Wellness, each operating between 30 and 80 dispensaries statewide. Despite the growth, Florida's program faced criticism for limited product diversity, high prices compared to adult-use states, and geographic access gaps in rural counties. The vertical integration model prevented independent cultivators from entering the market and limited patients' ability to access craft or boutique products. Wholesale pricing data from other states showed that independent cultivation markets typically produced 30 to 50 percent lower wholesale costs than vertically integrated systems, savings that translated to lower retail prices for patients.

The 2026 Rulemaking Process

The Florida Department of Health published a Notice of Proposed Rulemaking in September 2026, outlining the permanent licensing framework that would govern future MMTC applications. The proposed rule, designated as Florida Administrative Code Rule 64-4.XXX, established the $146,000 application fee, five-day application windows, and detailed scoring criteria for evaluating applicants. The rulemaking followed years of ad hoc license issuances and legal challenges, representing the state's first comprehensive attempt to codify a predictable, ongoing licensing process. The Department scheduled a 30-day public comment period and announced a public hearing for October 2026. Industry associations, patient advocates, and prospective applicants immediately raised concerns about the fee structure and compressed timelines, arguing that the framework favored incumbents and excluded smaller operators. The proposed rule did not include social equity provisions, minority business set-asides, or fee waivers for economically disadvantaged applicants, distinguishing Florida from states such as Illinois, New Jersey, and New York, which had implemented equity-focused licensing programs.

Key Players

Florida Department of Health

The Florida Department of Health, through its Office of Medical Marijuana Use (OMMU), administers the state's medical cannabis program and oversees MMTC licensing, patient registration, and regulatory compliance. The OMMU maintains the Medical Marijuana Use Registry, which tracks patient certifications, physician recommendations, and dispensing data. As of September 2026, the OMMU reported 823,000 active registered patients and 3,200 certified physicians authorized to recommend medical marijuana. The Department's proposed rulemaking authority derives from Florida Statutes § 381.986, which directs the agency to establish application procedures, qualification standards, and operational requirements for MMTCs. The Department has faced persistent criticism for slow license processing, inconsistent enforcement, and lack of transparency in scoring applications. The Florigrown verdict highlighted these concerns, and the 2026 proposed framework represented an effort to establish clearer, more defensible procedures.

Trulieve Cannabis Corp.

Trulieve operates the largest medical marijuana business in Florida, with more than 200 dispensaries and approximately 50 percent market share as of 2026. The company, headquartered in Quincy, Florida, was founded in 2015 as one of the original five low-THC licensees. Trulieve went public on the Canadian Securities Exchange in 2018 and expanded into multiple U.S. states through acquisitions, but Florida remained its core market, generating more than 60 percent of total revenue. Trulieve's dominance in Florida stemmed from early-mover advantages, aggressive retail expansion, and vertical integration efficiencies. The company operated cultivation facilities totaling more than 1.2 million square feet of canopy and produced a wide range of flower, concentrates, edibles, and topicals. Trulieve's political influence also drew scrutiny; the company and its executives contributed millions to Florida political campaigns, including substantial support for the failed 2024 adult-use legalization initiative. The proposed licensing framework posed both opportunities and risks for Trulieve. Additional licenses could dilute the company's market share, but high barriers to entry would limit the number of new competitors and potentially preserve Trulieve's dominant position.

Curaleaf Holdings, Inc.

Curaleaf, a multi-state operator based in Massachusetts, entered Florida in 2018 and operated more than 70 dispensaries in the state by 2026. The company ranked as the second-largest MMTC by dispensary count and held approximately 15 percent market share. Curaleaf's Florida operations included cultivation facilities in Alachua County and processing labs capable of producing flower, vape cartridges, edibles, and tinctures. Curaleaf's business model emphasized brand consistency across states, with standardized product lines and retail experiences. The company's scale and access to capital positioned it to compete effectively in any new licensing round, particularly given the $146,000 application fee and five-day windows that favored well-resourced operators.

Florida for Care and Patient Advocacy Groups

Florida for Care, a patient advocacy organization, led efforts to expand access to medical marijuana and reduce barriers for patients and small businesses. The group, founded in 2013, played a central role in drafting and promoting Amendment 2 in 2016. Florida for Care advocated for lower application fees, social equity provisions, and an end to vertical integration requirements, arguing that the existing framework concentrated market power among a few large operators and limited patient choice. In response to the 2026 proposed rules, Florida for Care submitted public comments criticizing the $146,000 fee as prohibitively expensive and calling for tiered licensing that would allow independent cultivators and retailers to enter the market. The organization also urged the Department of Health to implement fee waivers and technical assistance for minority-owned and veteran-owned businesses.

Florida Cannabis Action Network

The Florida Cannabis Action Network (Florida CAN), a grassroots advocacy group, focused on criminal justice reform, expungement, and equitable access to the cannabis industry. The organization opposed the proposed licensing framework on the grounds that it excluded communities disproportionately harmed by cannabis prohibition. Florida CAN pointed to data showing that Black Floridians were arrested for cannabis possession at nearly four times the rate of white residents, despite similar usage rates, and argued that any licensing expansion should prioritize applicants from affected communities. Florida CAN called for automatic expungement of prior cannabis convictions, social equity scoring criteria in license applications, and low-interest loans for equity applicants. The group also advocated for ending vertical integration and allowing microbusiness licenses for small-scale cultivators and retailers.

Legal and Regulatory Framework

Constitutional Authority: Amendment 2

Amendment 2 to the Florida Constitution, approved by voters in 2016, provides the constitutional foundation for the state's medical marijuana program. The amendment, codified as Article X, Section 29, guarantees the right of qualifying patients to use medical marijuana upon certification by a licensed physician. The amendment defines "debilitating medical condition" broadly and grants physicians discretion to certify patients for conditions of the same kind or class as those explicitly listed. Amendment 2 also mandates that the Department of Health issue MMTC licenses according to a formula tied to patient registration: one license for every 100,000 registered patients beyond the initial 250,000 threshold. This formula-based expansion mechanism has driven license issuance from 2017 through 2026, though the Department has discretion over the timing and structure of application windows.

Statutory Framework: Florida Statutes § 381.986

Florida Statutes § 381.986, enacted and amended by the Legislature between 2014 and 2026, establishes the operational requirements for MMTCs and the regulatory authority of the Department of Health. The statute requires MMTCs to operate as vertically integrated entities, controlling cultivation, processing, and dispensing. Licensees must demonstrate $5 million in liquid assets, maintain seed-to-sale tracking through the state's Metrc system, and comply with security, testing, and labeling standards. The statute authorizes the Department to establish application fees, qualification criteria, and operational rules through administrative rulemaking. The $146,000 application fee proposed in 2026 falls within the Department's statutory authority, though it represents a significant increase from the $60,063 fee charged in prior application rounds. The statute does not mandate social equity provisions, fee waivers, or minority business preferences, leaving such policies to the Department's discretion.

Administrative Rules: Florida Administrative Code Chapter 64-4

The Florida Administrative Code Chapter 64-4 contains the detailed regulations governing MMTC operations, including cultivation standards, product testing, packaging and labeling, and dispensing procedures. The proposed 2026 licensing framework would be codified within this chapter, establishing the procedures for future application windows. The proposed rule specifies that application windows will open for five consecutive business days, during which prospective applicants must submit complete applications including financial disclosures, business plans, security protocols, and evidence of technical expertise. Applications will be scored on a 100-point scale, with points awarded for cultivation experience, financial stability, diversity of ownership, and proposed geographic service areas. The Department will rank applications by score and issue licenses to the highest-scoring applicants, subject to background checks and final approval. The five-day window represents a departure from prior application rounds, which remained open for 30 to 60 days. The compressed timeline increases the risk of technical errors, incomplete submissions, and advantages for applicants with pre-existing relationships with regulatory consultants and legal counsel.

Federal Law and the Controlled Substances Act

Cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, 21 U.S.C. § 812, creating ongoing legal and financial risks for Florida MMTCs despite state-level authorization. Schedule I classification subjects cannabis businesses to Internal Revenue Code § 280E, which prohibits deductions for ordinary business expenses, resulting in effective federal tax rates of 70 percent or higher. MMTCs also face barriers to banking, as federally insured financial institutions risk money laundering charges under the Bank Secrecy Act for servicing cannabis businesses. The U.S. Department of Justice issued the Cole Memorandum in 2013, deprioritizing federal enforcement against state-legal cannabis businesses, but rescinded the memo in 2018. As of 2026, federal enforcement remained inconsistent, with occasional prosecutions of cannabis businesses for financial crimes or violations of state regulations. The federal-state conflict creates uncertainty for Florida licensees and complicates interstate commerce, capital formation, and intellectual property protection.

State-by-State Comparison of Licensing Frameworks

Florida's proposed $146,000 application fee and five-day windows contrast sharply with licensing structures in other medical and adult-use cannabis states, most of which feature lower fees, longer application periods, and tiered licensing systems.

California

California operates a tiered licensing system with separate licenses for cultivation, manufacturing, distribution, testing, and retail. Cultivation licenses range from $1,205 for micro-cultivators to $77,905 for large outdoor farms. Retail licenses cost $1,000 to apply and $5,000 annually. The state offers fee waivers for equity applicants in jurisdictions with social equity programs. Application windows remain open year-round on a rolling basis, allowing prospective licensees to apply at any time.

Illinois

Illinois implemented a social equity-focused licensing program in 2020, reserving a portion of adult-use licenses for applicants from communities disproportionately impacted by cannabis prohibition. Application fees for dispensary licenses totaled $5,000, with additional fees for cultivation and processing. The state awarded bonus points to applicants with majority ownership by minorities, women, veterans, or disabled individuals. Illinois also provided low-interest loans and technical assistance to equity applicants.

Michigan

Michigan charges $6,000 for adult-use retail licenses and $40,000 for Class C cultivation licenses (up to 2,000 plants). The state allows independent cultivation, processing, and retail operations, creating a competitive wholesale market. Application windows remain open continuously, and the state has issued more than 1,500 licenses since legalizing adult use in 2018. Michigan does not mandate vertical integration, and wholesale flower prices averaged $800 to $1,200 per pound in 2026, significantly lower than Florida's vertically integrated pricing.

New Jersey

New Jersey established a social equity program in 2021, prioritizing license applications from individuals with prior cannabis convictions, residents of economically disadvantaged areas, and minority-owned businesses. Application fees for cultivation licenses totaled $20,000, with reduced fees for equity applicants. The state issued conditional licenses to equity applicants before opening general applications, ensuring that social equity businesses had a head start in the market.

Oklahoma

Oklahoma operates one of the most open medical marijuana licensing systems in the United States, with $2,500 application fees for cultivation and retail licenses. The state does not cap the number of licenses and has issued more than 8,000 since 2018. Oklahoma's low barriers to entry created a highly competitive market with wholesale flower prices below $500 per pound, but also led to market saturation and financial distress among small operators.

State	Application Fee	License Type	Vertical Integration Required	Social Equity Provisions
Florida (proposed)	$146,000	Vertically integrated MMTC	Yes	No
California	$1,205 - $77,905	Tiered (cultivation, retail, etc.)	No	Yes (local programs)
Illinois	$5,000	Tiered	No	Yes (statewide)
Michigan	$6,000 - $40,000	Tiered	No	No
New Jersey	$20,000	Tiered	No	Yes (statewide)
Oklahoma	$2,500	Tiered	No	No

Market and Business Implications

Barriers to Entry and Market Consolidation

The $146,000 application fee, combined with the estimated $5 million to $15 million in capital required for vertical integration, effectively limits participation to well-funded multi-state operators and excludes smaller entrepreneurs. Industry analysts estimate that the total cost to launch a vertically integrated MMTC in Florida, including real estate, construction, equipment, inventory, and working capital, ranges from $10 million to $25 million. These capital requirements far exceed those in states with tiered licensing, where independent retailers can enter the market with $250,000 to $500,000 in startup costs. The high barriers to entry favor incumbents and multi-state operators with access to institutional capital, debt financing, and operational expertise. Trulieve, Curaleaf, and other established MMTCs can leverage existing infrastructure, brand recognition, and regulatory relationships to compete in new application rounds. Smaller applicants, particularly those without prior cannabis industry experience, face significant disadvantages in securing financing, assembling application materials, and navigating the five-day submission window. Market consolidation has already defined Florida's medical marijuana industry, with the top five operators controlling approximately 75 percent of total sales. The proposed licensing framework would likely perpetuate this concentration unless the state issues licenses at scale or implements structural reforms such as ending vertical integration or creating microbusiness license categories.

Impact on Wholesale Pricing and Product Diversity

Vertical integration in Florida has resulted in higher wholesale costs and limited product diversity compared to states with independent cultivation and retail tiers. In competitive wholesale markets such as Colorado, Oregon, and Michigan, wholesale flower prices ranged from $500 to $1,200 per pound in 2026, driven by competition among hundreds of independent cultivators. Florida's vertically integrated operators, by contrast, transfer flower internally at prices estimated at $1,500 to $2,500 per pound, costs that translate to higher retail prices for patients. Retail flower prices in Florida averaged $40 to $60 per eighth-ounce in 2026, compared to $20 to $35 in mature adult-use markets such as Colorado and California. Patients in Florida also faced limited access to craft or boutique products, as the 25 MMTCs focused on high-volume, standardized strains rather than small-batch, terpene-rich cultivars. Independent cultivators in states like California and Oregon produced hundreds of distinct strains, including rare landrace genetics and experimental hybrids, creating product diversity that Florida's vertically integrated model could not replicate. The proposed licensing framework would not address these structural issues unless the state issued a significant number of new licenses or reformed the vertical integration requirement. Patient advocates argued that ending vertical integration and allowing independent cultivation would reduce costs, increase product variety, and create opportunities for craft producers.

Capital Flows and Investor Sentiment

The announcement of the proposed licensing framework generated mixed reactions among cannabis investors, with multi-state operators expressing cautious optimism and smaller investors raising concerns about market access. Publicly traded MMTCs such as Trulieve and Curaleaf saw modest stock price increases following the announcement, as investors anticipated that high barriers to entry would limit new competition. Analysts at Viridian Capital Advisors noted that the $146,000 fee and five-day windows would favor established operators with regulatory expertise and capital reserves. Private equity and venture capital investors, however, expressed skepticism about the framework's impact on smaller operators and social equity applicants. Several investors told industry publications that the lack of equity provisions and the high application costs would deter investment in Florida-based startups, redirecting capital to states with more inclusive licensing structures. The compressed application windows also increased risk for investors, as technical errors or incomplete submissions could result in forfeited application fees and lost opportunities. The proposed framework also raised questions about the state's long-term commitment to expanding the medical marijuana market versus protecting incumbents. If the Department of Health issued only a small number of licenses in each application round, the framework would function as a de facto cap, preserving market share for existing operators and limiting patient benefits from increased competition.

What Experts Say

Industry analysts, patient advocates, and legal experts have offered divergent assessments of the proposed licensing framework, with opinions shaped by stakeholder interests and policy priorities. According to Morgan Fox, a cannabis policy analyst and former spokesperson for the National Cannabis Industry Association, the $146,000 application fee represents a significant barrier to entry that could exclude smaller operators and social equity applicants. Fox noted in public comments that states with high application fees and compressed timelines tend to favor well-capitalized multi-state operators over local entrepreneurs, reducing market diversity and limiting patient choice. Karen Goldstein, executive director of Florida for Care, characterized the proposed framework as a missed opportunity to expand access and promote equity. Goldstein stated in a press release that the lack of social equity provisions and the high application costs would perpetuate the dominance of a few large operators and fail to address the harms of cannabis prohibition. She called on the Department of Health to implement fee waivers, technical assistance programs, and scoring preferences for minority-owned and veteran-owned businesses. John Lockwood, a cannabis attorney at Akerman LLP in Tallahassee, described the five-day application windows as operationally challenging for applicants. Lockwood explained in an interview with a Florida business publication that assembling a complete application—including financial disclosures, business plans, security protocols, and real estate documentation—typically requires weeks or months of preparation. The compressed timeline, he argued, would favor applicants with pre-existing relationships with regulatory consultants and legal counsel, creating an uneven playing field. Steve Schain, a cannabis attorney and managing partner at Hoban Law Group, noted that Florida's vertical integration requirement distinguishes the state from most other medical and adult-use markets. Schain observed that vertical integration increases capital requirements, limits product diversity, and reduces competition, but also simplifies regulatory oversight and seed-to-sale tracking. He suggested that the state could achieve similar regulatory goals through robust testing and tracking requirements without mandating vertical integration. Patient advocates emphasized the impact of the licensing framework on access and affordability. Jodi James, co-founder of the Florida Cannabis Action Network, argued that the proposed rules would do little to reduce prices or expand product options for patients. James pointed to data from other states showing that competitive wholesale markets and independent cultivation reduce retail prices by 30 to 50 percent, savings that Florida patients could not access under the current vertically integrated model.

What's Next

The Florida Department of Health will accept public comments on the proposed licensing framework through October 15, 2026, followed by a public hearing scheduled for October 22, 2026, in Tallahassee. The Department will review comments and testimony before finalizing the rule, a process that typically takes 60 to 90 days. If the rule is adopted as proposed, the first application window could open as early as January 2027. Key decision points and scenarios include:

• Public Comment and Revisions: The Department could revise the proposed rule in response to public comments, potentially reducing the application fee, extending the application window, or adding social equity provisions. However, significant changes would require additional rulemaking and delay implementation.
• Legal Challenges: Unsuccessful applicants or advocacy groups could file lawsuits challenging the rule on grounds of procedural irregularity, lack of transparency, or violation of Amendment 2's intent. Litigation could delay or block implementation, as occurred with prior licensing rounds.
• Legislative Intervention: The Florida Legislature could pass legislation amending Florida Statutes § 381.986 to mandate lower fees, social equity provisions, or an end to vertical integration. However, such reforms would require bipartisan support and could face opposition from incumbent licensees.
• Federal Rescheduling: The U.S. Drug Enforcement Administration's ongoing review of cannabis scheduling could result in reclassification to Schedule III or descheduling, eliminating Internal Revenue Code § 280E tax penalties and expanding access to banking. Federal reform would reduce financial barriers for Florida MMTCs and prospective applicants, but would not directly impact state licensing structures.
• Adult-Use Legalization: Florida voters could approve an adult-use legalization initiative in a future election, fundamentally reshaping the state's cannabis market. Adult-use legalization would likely trigger a new licensing framework, potentially with separate license categories for medical and adult-use operators.

Industry observers expect the Department to issue a limited number of licenses in the first application round, likely 5 to 10, to gauge market response and minimize disruption to existing operators. Subsequent rounds would depend on patient registration growth and the Department's assessment of market demand. If the formula in Amendment 2 continues to drive license issuance, Florida could reach 30 to 35 active MMTCs by 2028, assuming patient registration continues to grow at 5 to 10 percent annually. The proposed framework also raises broader questions about Florida's cannabis policy trajectory. The state has historically favored restrictive, vertically integrated models that limit competition and concentrate market power among a few large operators. Whether Florida will shift toward more inclusive, equity-focused policies—as seen in Illinois, New Jersey, and New York—remains uncertain and will depend on political leadership, advocacy efforts, and public pressure.

Further Reading

• Florida Department of Health, Office of Medical Marijuana Use: https://knowthefactsmmj.com/
• Florida Statutes § 381.986 (Medical Use of Marijuana): http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0300-0399/0381/Sections/0381.986.html
• Florida Administrative Code Chapter 64-4 (Medical Marijuana): https://www.flrules.org/gateway/ChapterHome.asp?Chapter=64-4
• Amendment 2 to the Florida Constitution (2016): https://dos.myflorida.com/elections/for-voters/constitutional-amendments/
• Florida for Care: https://www.floridaforcare.org/
• Florida Cannabis Action Network: https://flcan.org/
• Florigrown v. Florida Department of Health case documents: Leon County Circuit Court Case No. 2018-CA-002549
• Viridian Capital Advisors cannabis market research: https://www.viridianca.com/
• National Cannabis Industry Association policy resources: https://thecannabisindustry.org/
• U.S. Controlled Substances Act, 21 U.S.C. § 812: https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm